Kun Pharmaceutical Group Osteoporosis Therapeutics Clinical Trial Application Accepted

Innovative clinical application
the new drug to the United States Amin company has been listed abroad monoclonal antibody drug tinnomonotada (hereinafter referred to as "tinnomonotada") injection as a imitation target, the development of amino acid sequence and tinol monoantigen is completely consistent with the national biological products of the second class of new drugs - therapeutic all-human source RANKL monoclonal antibody injection, for the treatment of high risk of fractures of the menopausal female osteoporosisthe current clinical treatment program of osteoporosis in China mainly to bisphosphonates, estrogen, estrogen receptor regulators and calcite-reducing traditional small molecules, hormones and peptide drugs, so tinnoprosy as the first single-clone antibody based on RANKL, in clinical applications are innovativethe development of rankL-based tnobutiais is a new drug listed in the field of osteoporosis in recent years, its clinical application is wide, tinnota in foreign (UK and UK) the main guidelines have occupied an important therapeutic positionAnjin company's tinnitus resistance is still the current domestic and foreign RANKL target approved for osteoporosis mono-drugs, domestic enterprises have related varieties in research and development, but so far there is still no domestic for osteoporosis RANKL inhibitors listedthe gospel of osteoporosis in middle-aged and elderly women
in 2018, Tinocno has global sales of approximately $4 billion, with a CAGR of 21% over the past five years and forecast sales of more than $5 billion in 2020Tintnomonota has been listed in the United States, several countries in Europe and Japan, and in May 2019, Amgen's Tinocnomono-resistant (domesticname "ground-comfort" ) with a specification of 120mg/bottle was approved by NMPA for treatment of non-surgical lycitomas or adolescents with severe functional impairmentsThe tnostomy of postmenopausal women with osteoporosis, which is currently targeted at an increased risk of fractures, has not yet been listed in ChinaOctober 2018, the first Chinese epidemiological survey of osteoporosis published by the National Health and Reform Commission showed that the prevalence of osteoporosis in people over 50 years of age was 19.2%, with 6.0% for men and 32.1% for womenThe main conclusions obtained by the survey show that osteoporosis has become an important health problem in the population over 50 years of age in China, especially the problem of osteoporosis in middle-aged and elderly womenTherefore, after the success of research and development, for china's middle-aged and elderly women osteoporosis patients bring health gospelThe research and development ofmonobiotic similar ity is one of the important achievements of Kun pharma's strategic layout in the field of biopharmaceuticals, while Tinnomonoist, as a potential heavyweight product for osteoporosis therapy in China, is highly consistent with the main coverage areas of the treatment currently covered by Baker Norton, a subsidiary of Kun Pharmain recent years, Kun Medicine has established four research and development centers in Yunnan, Beijing, Shanghai and North America, and has formed the layout of traditional Chinese medicine, chemical medicine, biopharmaceutical scouncina, independent research and development, external cooperation, investment in multi-channel innovation and developmentIn the future, Kun medicine will continue to adhere to the development of innovative drugs, and strive to develop into a leading domestic, international advanced innovative pharmaceutical enterprises.